# A Prospective Study on Optimizing Treatment for ABPA

> **NCT05129033** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Allergic Bronchopulmonary Aspergillosis

## Interventions

- **DRUG:** Prednisone tablet
- **DRUG:** itraconazole
- **BIOLOGICAL:** Omalizumab

## Key facts

- **NCT ID:** NCT05129033
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-15
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129033, "A Prospective Study on Optimizing Treatment for ABPA". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05129033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*